{"title":"胱抑素 C 和 eGFRCKD-EPI-CysC：诊断多发性骨髓瘤肾功能损伤和两年无进展生存期的新型生物标记物。","authors":"Jian Niu, Jiajia Yu, Huifang Huang, Jinfang Shi, Dong Zheng, Jun Qiu","doi":"10.1080/00365513.2023.2297364","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate cystatin C (CysC) and estimation of glomerular filtration rate (GFR) calculated using the formula, CKD-EPI-CysC (eGFR<sub>CKD-EPI-CysC</sub>) for renal impairment diagnosis and predicting the prognosis of patients with multiple myeloma (MM). One hundred-fourteen patients with MM and 38 healthy individuals were recruited for the study. Data on clinical characteristics and renal function-related biochemical indicators were collected and analyzed. Patients with MM had increased levels of CysC (1.25 (0.97-2.31) vs. 0.84 (0.80-0.92), respectively, <i>p</i> < 0.001) and decreased levels of eGFR<sub>CKD-EPI-CysC</sub> (53.0 (24.4-81.1) vs. 97.2 (87.0-104.5), respectively, <i>p</i> < 0.001), compared with healthy individuals. There were significantly more patients with elevated CysC levels than with elevated sCr levels (64.9% vs. 41.2%, respectively, <i>p</i> < 0.001). The CKD-EPI-CysC formula detected more patients with eGFR < 60 ml/(min × 1.73 m<sup>2</sup>) than the CKD-EPI-sCr formula (52.63% vs. 37.72%, respectively, <i>p</i> < 0.001). Correlation analysis found that only CysC, eGFR<sub>CKD-EPI-CysC</sub>, and eGFR<sub>CKD-EPI-sCr-CysC</sub> strongly correlated with β<sub>2</sub>-microglobulin in group ISS-I. Logistic regression analysis was used to screen CysC (<i>OR</i> = 1.495, 95% <i>CI</i> = 1.097-2.038, <i>p</i> = 0.011) and eGFR<sub>CKD-EPI-CysC</sub> (<i>OR</i> = 0.980, 95% <i>CI</i> = 0.967-0.993, <i>p</i> = 0.003) as independent prognostic indicators for 2-year-progression-free survival (PFS) of patients with MM. Receiver operating characteristic curve analysis found that CysC values >1.70 mg/L had 67.6% sensitivity and 65.2% specificity and eGFR<sub>CKD-EPI-CysC</sub> values <38.62 ml/(min × 1.73 m<sup>2</sup>) had 65.2% sensitivity and 67.6% specificity for 2-year PFS of patients with MM. In summary, CysC and eGFR<sub>CKD-EPI-CysC</sub> were more sensitive than sCr and eGFR<sub>CKD-EPI-sCr</sub> for predicting renal impairment in patients newly diagnosed with MM. Increased CysC and decreased eGFR<sub>CKD-EPI-CysC</sub> levels were effective predictors of 2-year PFS of patients with MM.</p>","PeriodicalId":21474,"journal":{"name":"Scandinavian Journal of Clinical & Laboratory Investigation","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cystatin C and eGFR<sub>CKD-EPI-CysC</sub>: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma.\",\"authors\":\"Jian Niu, Jiajia Yu, Huifang Huang, Jinfang Shi, Dong Zheng, Jun Qiu\",\"doi\":\"10.1080/00365513.2023.2297364\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>To evaluate cystatin C (CysC) and estimation of glomerular filtration rate (GFR) calculated using the formula, CKD-EPI-CysC (eGFR<sub>CKD-EPI-CysC</sub>) for renal impairment diagnosis and predicting the prognosis of patients with multiple myeloma (MM). One hundred-fourteen patients with MM and 38 healthy individuals were recruited for the study. Data on clinical characteristics and renal function-related biochemical indicators were collected and analyzed. Patients with MM had increased levels of CysC (1.25 (0.97-2.31) vs. 0.84 (0.80-0.92), respectively, <i>p</i> < 0.001) and decreased levels of eGFR<sub>CKD-EPI-CysC</sub> (53.0 (24.4-81.1) vs. 97.2 (87.0-104.5), respectively, <i>p</i> < 0.001), compared with healthy individuals. There were significantly more patients with elevated CysC levels than with elevated sCr levels (64.9% vs. 41.2%, respectively, <i>p</i> < 0.001). The CKD-EPI-CysC formula detected more patients with eGFR < 60 ml/(min × 1.73 m<sup>2</sup>) than the CKD-EPI-sCr formula (52.63% vs. 37.72%, respectively, <i>p</i> < 0.001). Correlation analysis found that only CysC, eGFR<sub>CKD-EPI-CysC</sub>, and eGFR<sub>CKD-EPI-sCr-CysC</sub> strongly correlated with β<sub>2</sub>-microglobulin in group ISS-I. Logistic regression analysis was used to screen CysC (<i>OR</i> = 1.495, 95% <i>CI</i> = 1.097-2.038, <i>p</i> = 0.011) and eGFR<sub>CKD-EPI-CysC</sub> (<i>OR</i> = 0.980, 95% <i>CI</i> = 0.967-0.993, <i>p</i> = 0.003) as independent prognostic indicators for 2-year-progression-free survival (PFS) of patients with MM. Receiver operating characteristic curve analysis found that CysC values >1.70 mg/L had 67.6% sensitivity and 65.2% specificity and eGFR<sub>CKD-EPI-CysC</sub> values <38.62 ml/(min × 1.73 m<sup>2</sup>) had 65.2% sensitivity and 67.6% specificity for 2-year PFS of patients with MM. In summary, CysC and eGFR<sub>CKD-EPI-CysC</sub> were more sensitive than sCr and eGFR<sub>CKD-EPI-sCr</sub> for predicting renal impairment in patients newly diagnosed with MM. Increased CysC and decreased eGFR<sub>CKD-EPI-CysC</sub> levels were effective predictors of 2-year PFS of patients with MM.</p>\",\"PeriodicalId\":21474,\"journal\":{\"name\":\"Scandinavian Journal of Clinical & Laboratory Investigation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Clinical & Laboratory Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/00365513.2023.2297364\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Clinical & Laboratory Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00365513.2023.2297364","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
目的：评估胱抑素C（CysC）和使用CKD-EPI-CysC（eGFRCKD-EPI-CysC）公式计算的肾小球滤过率（GFR）估算值，用于多发性骨髓瘤（MM）患者的肾功能损害诊断和预后预测。研究共招募了 14 名 MM 患者和 38 名健康人。研究收集并分析了临床特征和肾功能相关生化指标的数据。MM患者的CysC（1.25 (0.97-2.31) vs. 0.84 (0.80-0.92), p CKD-EPI-CysC（53.0 (24.4-81.1) vs. 97.2 (87.0-104.5），分别 p p 2）比 CKD-EPI-sCr 公式（52.63% vs. 37.72%，分别 p CKD-EPI-CysC，eGFRCKD-EPI-sCr-CysC 与 ISS-I 组的β2-微球蛋白密切相关。利用逻辑回归分析筛选出 CysC（OR = 1.495，95% CI = 1.097-2.038，p = 0.011）和 eGFRCKD-EPI-CysC（OR = 0.980，95% CI = 0.967-0.993，p = 0.003）作为 MM 患者 2 年无进展生存期（PFS）的独立预后指标。接收者操作特征曲线分析发现，CysC值>1.70 mg/L对MM患者2年无进展生存期的敏感性为67.6%，特异性为65.2%；eGFRCKD-EPI-CysC值2)对MM患者2年无进展生存期的敏感性为65.2%，特异性为67.6%。总之，CysC 和 eGFRCKD-EPI-CysC 比 sCr 和 eGFRCKD-EPI-sCr 对预测新诊断为 MM 患者的肾功能损害更敏感。CysC水平升高和eGFRCKD-EPI-CysC水平降低可有效预测MM患者的2年PFS。
Cystatin C and eGFRCKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma.
To evaluate cystatin C (CysC) and estimation of glomerular filtration rate (GFR) calculated using the formula, CKD-EPI-CysC (eGFRCKD-EPI-CysC) for renal impairment diagnosis and predicting the prognosis of patients with multiple myeloma (MM). One hundred-fourteen patients with MM and 38 healthy individuals were recruited for the study. Data on clinical characteristics and renal function-related biochemical indicators were collected and analyzed. Patients with MM had increased levels of CysC (1.25 (0.97-2.31) vs. 0.84 (0.80-0.92), respectively, p < 0.001) and decreased levels of eGFRCKD-EPI-CysC (53.0 (24.4-81.1) vs. 97.2 (87.0-104.5), respectively, p < 0.001), compared with healthy individuals. There were significantly more patients with elevated CysC levels than with elevated sCr levels (64.9% vs. 41.2%, respectively, p < 0.001). The CKD-EPI-CysC formula detected more patients with eGFR < 60 ml/(min × 1.73 m2) than the CKD-EPI-sCr formula (52.63% vs. 37.72%, respectively, p < 0.001). Correlation analysis found that only CysC, eGFRCKD-EPI-CysC, and eGFRCKD-EPI-sCr-CysC strongly correlated with β2-microglobulin in group ISS-I. Logistic regression analysis was used to screen CysC (OR = 1.495, 95% CI = 1.097-2.038, p = 0.011) and eGFRCKD-EPI-CysC (OR = 0.980, 95% CI = 0.967-0.993, p = 0.003) as independent prognostic indicators for 2-year-progression-free survival (PFS) of patients with MM. Receiver operating characteristic curve analysis found that CysC values >1.70 mg/L had 67.6% sensitivity and 65.2% specificity and eGFRCKD-EPI-CysC values <38.62 ml/(min × 1.73 m2) had 65.2% sensitivity and 67.6% specificity for 2-year PFS of patients with MM. In summary, CysC and eGFRCKD-EPI-CysC were more sensitive than sCr and eGFRCKD-EPI-sCr for predicting renal impairment in patients newly diagnosed with MM. Increased CysC and decreased eGFRCKD-EPI-CysC levels were effective predictors of 2-year PFS of patients with MM.
期刊介绍：
The Scandinavian Journal of Clinical and Laboratory Investigation is an international scientific journal covering clinically oriented biochemical and physiological research. Since the launch of the journal in 1949, it has been a forum for international laboratory medicine, closely related to, and edited by, The Scandinavian Society for Clinical Chemistry.
The journal contains peer-reviewed articles, editorials, invited reviews, and short technical notes, as well as several supplements each year. Supplements consist of monographs, and symposium and congress reports covering subjects within clinical chemistry and clinical physiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
